RxDoctor Payments Data

Lisa Fadden

Family · Moon Township, PANPI 1992995971

Payments from drug & device makers

$7,304in general payments, 2019–2025

Across 320 payments — averaging $22.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$704
  • Daiichi Sankyo Inc.$498
  • Ardelyx, Inc.$478
  • Pfizer$288
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$7,11797%
  • Education$1873%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,304 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$181,404
Medicare patients
351
Services billed
6,689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates577$41,003
CreonLipase/Protease/Amylase13$39,349
LinzessLinaclotide13$7,706
SutabSod Sulf/Pot Chloride/Mag Sulf38$6,020
Mesalamine11$5,385
Sucralfate25$2,902
CholestyramineCholestyramine (With Sugar)31$2,721
Omeprazole311$2,264
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C14$1,910
Famotidine183$1,806
Colestipol Hcl13$1,325
Lubiprostone15$1,320
Pantoprazole Sodium140$1,243
Balsalazide Disodium15$941
Sulfasalazine17$552

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$2,345$47,05526 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$227$1,91014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.

Other family in Moon Township

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →